Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315702832> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4315702832 endingPage "e35" @default.
- W4315702832 startingPage "e35" @default.
- W4315702832 abstract "Objective: Non-alcoholic fatty liver disease (NAFLD) is a multifactorial pathological syndrome characterized by lipid accumulation in hepatocytes. This can lead to non-alcoholic steatohepatitis (NASH) which can progress to liver fibrosis, cirrhosis and liver cancer. Unfortunately, the pathogenesis of NAFLD is still unknown. However, current studies suggest that gliflozins, primarily antidiabetics, could have beneficial effects on liver metabolism. The aim of this study was therefore to examine whether empagliflozin (10 mg.kg-1.day-1 in drinking fluid) will have beneficial effects. Design and methods: NAFLD was induced by eight weeks of high-fat diet feeding (60% protein) in adult (6-month-old) spontaneously hypertensive rats (SHR). Control SHR were fed a standard diet. Then, the animals were either untreated or treated with empagliflozin for eight weeks. The evaluation of renal function (metabolic cages) and oral glucose tolerance (OGT) test were performed before the start of the treatment and at the end of the study. Cardiac function evaluated by echocardiography as well as metabolic parameters in serum and in liver were determined at the end of the experiment. Results: High-fat diet feeding increased body weight and visceral adiposity. Moreover, it worsened insulin resistance (evaluated as OGT test). In addition, it induced increase in triglycerides and cholesterol levels. Although it had no effect on renal function, it substantially deteriorated not only systolic but also diastolic function of the heart in SHR rats. Empagliflozin had no effect on body weight or visceral fat deposition but improved insulin sensitivity (OGT test) and several metabolic parameters (plasma insulin, non-esterified fatty acids, uric acid and HDL-cholesterol). Moreover, it had beneficial effects on systolic (fractional shortening) and especially diastolic (PWTd, RWT, and E/A ratio) function. Conclusions: Our results demonstrated that the treatment with empagliflozin had beneficial hepatoprotective and cardioprotective actions in hypertensive rats with experimentally induced non-alcoholic liver fatty disease." @default.
- W4315702832 created "2023-01-12" @default.
- W4315702832 creator A5040702446 @default.
- W4315702832 creator A5042598659 @default.
- W4315702832 creator A5042837368 @default.
- W4315702832 creator A5058561365 @default.
- W4315702832 creator A5078212495 @default.
- W4315702832 creator A5087462714 @default.
- W4315702832 date "2023-01-01" @default.
- W4315702832 modified "2023-10-02" @default.
- W4315702832 title "S-12-3: BENEFICIAL EFFECTS OF EMPAGLIFLOZIN ON METABOLIC PARAMETERS AND DIASTOLIC FUNCTION IN SPONTANEOUSLY HYPERTENSIVE RATS FED A HIGH-FAT DIET" @default.
- W4315702832 doi "https://doi.org/10.1097/01.hjh.0000913036.58793.f1" @default.
- W4315702832 hasPublicationYear "2023" @default.
- W4315702832 type Work @default.
- W4315702832 citedByCount "0" @default.
- W4315702832 crossrefType "journal-article" @default.
- W4315702832 hasAuthorship W4315702832A5040702446 @default.
- W4315702832 hasAuthorship W4315702832A5042598659 @default.
- W4315702832 hasAuthorship W4315702832A5042837368 @default.
- W4315702832 hasAuthorship W4315702832A5058561365 @default.
- W4315702832 hasAuthorship W4315702832A5078212495 @default.
- W4315702832 hasAuthorship W4315702832A5087462714 @default.
- W4315702832 hasBestOaLocation W43157028321 @default.
- W4315702832 hasConcept C126322002 @default.
- W4315702832 hasConcept C134018914 @default.
- W4315702832 hasConcept C2775887513 @default.
- W4315702832 hasConcept C2777180221 @default.
- W4315702832 hasConcept C2777214474 @default.
- W4315702832 hasConcept C2777391703 @default.
- W4315702832 hasConcept C2778772119 @default.
- W4315702832 hasConcept C2779134260 @default.
- W4315702832 hasConcept C2779306644 @default.
- W4315702832 hasConcept C2779478299 @default.
- W4315702832 hasConcept C2780578515 @default.
- W4315702832 hasConcept C555293320 @default.
- W4315702832 hasConcept C71924100 @default.
- W4315702832 hasConceptScore W4315702832C126322002 @default.
- W4315702832 hasConceptScore W4315702832C134018914 @default.
- W4315702832 hasConceptScore W4315702832C2775887513 @default.
- W4315702832 hasConceptScore W4315702832C2777180221 @default.
- W4315702832 hasConceptScore W4315702832C2777214474 @default.
- W4315702832 hasConceptScore W4315702832C2777391703 @default.
- W4315702832 hasConceptScore W4315702832C2778772119 @default.
- W4315702832 hasConceptScore W4315702832C2779134260 @default.
- W4315702832 hasConceptScore W4315702832C2779306644 @default.
- W4315702832 hasConceptScore W4315702832C2779478299 @default.
- W4315702832 hasConceptScore W4315702832C2780578515 @default.
- W4315702832 hasConceptScore W4315702832C555293320 @default.
- W4315702832 hasConceptScore W4315702832C71924100 @default.
- W4315702832 hasIssue "Suppl 1" @default.
- W4315702832 hasLocation W43157028321 @default.
- W4315702832 hasLocation W43157028322 @default.
- W4315702832 hasOpenAccess W4315702832 @default.
- W4315702832 hasPrimaryLocation W43157028321 @default.
- W4315702832 hasRelatedWork W138803513 @default.
- W4315702832 hasRelatedWork W1967657502 @default.
- W4315702832 hasRelatedWork W1986132654 @default.
- W4315702832 hasRelatedWork W2010140898 @default.
- W4315702832 hasRelatedWork W2024020128 @default.
- W4315702832 hasRelatedWork W2082140668 @default.
- W4315702832 hasRelatedWork W2278593945 @default.
- W4315702832 hasRelatedWork W2368901575 @default.
- W4315702832 hasRelatedWork W4234612679 @default.
- W4315702832 hasRelatedWork W1723406454 @default.
- W4315702832 hasVolume "41" @default.
- W4315702832 isParatext "false" @default.
- W4315702832 isRetracted "false" @default.
- W4315702832 workType "article" @default.